Summary

The global Sulfonylureas for Type 2 Diabetes market size is predicted to grow from US$ 26010 million in 2025 to US$ 36520 million in 2032; it is expected to grow at a CAGR of 5.1% from 2026 to 2032.
In 2024, global Sulfonylureas for Type 2 Diabetes production reached approximately 4336.42 M Units, with an average global market price of around 5.84 USD per Unit. The global prevalence of type 2 diabetes continues to rise, with an expanding number of high-risk groups such as the middle-aged and elderly, and obese individuals. Some hypoglycemic drugs have limited efficacy in controlling blood sugar or significant adverse reactions. Sulfonylureas, however, balance the core needs of ""achieving therapeutic goals"" and ""safe medication"" with their potent blood sugar-lowering effects and optimized safety profile. They are particularly suitable for high-risk groups such as the middle-aged and elderly, and those with underlying medical conditions, eliminating clinical concerns about ""unstable blood sugar control"" or ""excessive risk."" As a classic oral hypoglycemic agent for the treatment of type 2 diabetes, sulfonylureas precisely address the core pain points in clinical treatment, and their market potential continues to expand against the backdrop of a continuously rising global demand for diabetes prevention and control.
Sulfonylureas are a class of oral medications used primarily to treat Type 2 Diabetes Mellitus. They are among the oldest and most widely used anti-diabetic drugs, known for their high efficacy and relatively low cost.Sulfonylureas for Type 2 Diabetes are mainly divided into Glibenclamide, Glipizide, Gliclazide, Glizidone, and Glimepiride, which have advantages such as strong hypoglycemic effect, milder side effects, and more convenient dosing frequency.
The upstream raw materials for Sulfonylureas for Type 2 Diabetes mainly include active ingredients such as glibenclamide, glipizide, gliclazide, glimepiride, and glimepiride. Typical suppliers include AGC Pharma Chemicals, ICROM, Gedeon Richter, and Dr. Reddy's Laboratories. Downstream applications are mainly in hospitals and pharmacies. The single-line production capacity of Sulfonylureas for Type 2 Diabetes varies significantly depending on the dosage form and production scale, with annual production capacity typically ranging from 50 million to 150 million tablets, and gross profit margins usually between 30% and 50%.
United States market for Sulfonylureas for Type 2 Diabetes is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Sulfonylureas for Type 2 Diabetes is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Sulfonylureas for Type 2 Diabetes is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Sulfonylureas for Type 2 Diabetes players cover Sanofi, Pfizer, Teva, AdvaCare Pharma, Krka, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Sulfonylureas for Type 2 Diabetes Industry Forecast” looks at past sales and reviews total world Sulfonylureas for Type 2 Diabetes sales in 2025, providing a comprehensive analysis by region and market sector of projected Sulfonylureas for Type 2 Diabetes sales for 2026 through 2032. With Sulfonylureas for Type 2 Diabetes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sulfonylureas for Type 2 Diabetes industry.
This Insight Report provides a comprehensive analysis of the global Sulfonylureas for Type 2 Diabetes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sulfonylureas for Type 2 Diabetes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sulfonylureas for Type 2 Diabetes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sulfonylureas for Type 2 Diabetes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sulfonylureas for Type 2 Diabetes.
This report presents a comprehensive overview, market shares, and growth opportunities of Sulfonylureas for Type 2 Diabetes market by product type, application, key manufacturers and key regions and countries.
Market Segmentation
Segmentation by Type:
Glibenclamide
Glipizide
Gliclazide
Glizidone
Glimepiride
Segmentation by Patent:
Original Drug
Generic Drug
Segmentation by Application:
Hospital
Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Pfizer
Teva
AdvaCare Pharma
Krka
Lupin Healthcare
Viatris (Mylan)
Apotex Corporation
Hoechst Canada
Hikma Pharmaceuticals
Servier Laboratories
Aurobindo Pharma
Zydus Cadila Healthcare
Accord Healthcare
Taj Pharma
Boehringer Ingelheim
Qingdao Double Whale Pharmaceutical
CHANGZHOU SUNLIGHT PHARMACEUTICAL
Zhejiang Shapuaisi Pharmaceutical
DISHA PHARMACEUTICAL GROUP
Shandong Lukang Pharmaceutical
Beijing Jingfeng pharmaceutical
Suzhou Zhonghua Pharmaceutical Industry
Shanghai SINE United Pharmaceuticals
Zhuhai United Pharmaceutical
Changzhou Siyao Pharmaceuticals
Shijiazhuang Yiling Pharmaceutical
Jiangsu Vanguard Pharmaceutical
China Resources Shuanghe Pharmaceutical
TIPR PHARMACEUTICAL
Jilin Jinheng Pharmaceutical
Wanbang Biopharmaceuticals
Cspc Holdings Company
Key Questions Addressed in this Report
What is the 10-year outlook for the global Sulfonylureas for Type 2 Diabetes market?
What factors are driving Sulfonylureas for Type 2 Diabetes market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Sulfonylureas for Type 2 Diabetes market opportunities vary by end market size?
How does Sulfonylureas for Type 2 Diabetes break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Sulfonylureas for Type 2 Diabetes Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Sulfonylureas for Type 2 Diabetes by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Sulfonylureas for Type 2 Diabetes by Country/Region, 2021, 2025 & 2032
2.2 Sulfonylureas for Type 2 Diabetes Segment by Type
2.2.1 Glibenclamide
2.2.2 Glipizide
2.2.3 Gliclazide
2.2.4 Glizidone
2.2.5 Glimepiride
2.2.6 Sulfonylureas for Type 2 Diabetes Sales by Type
2.2.6.1 Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Type (2021-2026)
2.2.6.2 Global Sulfonylureas for Type 2 Diabetes Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Sulfonylureas for Type 2 Diabetes Sale Price by Type (2021-2026)
2.3 Sulfonylureas for Type 2 Diabetes Segment by Patent
2.3.1 Original Drug
2.3.2 Generic Drug
2.3.3 Sulfonylureas for Type 2 Diabetes Sales by Patent
2.3.3.1 Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Patent (2021-2026)
2.3.3.2 Global Sulfonylureas for Type 2 Diabetes Revenue and Market Share by Patent (2021-2026)
2.3.3.3 Global Sulfonylureas for Type 2 Diabetes Sale Price by Patent (2021-2026)
2.4 Sulfonylureas for Type 2 Diabetes Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Sulfonylureas for Type 2 Diabetes Sales by Application
2.4.3.1 Global Sulfonylureas for Type 2 Diabetes Sale Market Share by Application (2021-2026)
2.4.3.2 Global Sulfonylureas for Type 2 Diabetes Revenue and Market Share by Application (2021-2026)
2.4.3.3 Global Sulfonylureas for Type 2 Diabetes Sale Price by Application (2021-2026)

3 Global by Company
3.1 Global Sulfonylureas for Type 2 Diabetes Breakdown Data by Company
3.1.1 Global Sulfonylureas for Type 2 Diabetes Annual Sales by Company (2021-2026)
3.1.2 Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Company (2021-2026)
3.2 Global Sulfonylureas for Type 2 Diabetes Annual Revenue by Company (2021-2026)
3.2.1 Global Sulfonylureas for Type 2 Diabetes Revenue by Company (2021-2026)
3.2.2 Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Company (2021-2026)
3.3 Global Sulfonylureas for Type 2 Diabetes Sale Price by Company
3.4 Key Manufacturers Sulfonylureas for Type 2 Diabetes Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Sulfonylureas for Type 2 Diabetes Product Location Distribution
3.4.2 Players Sulfonylureas for Type 2 Diabetes Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 World Historic Review for Sulfonylureas for Type 2 Diabetes by Geographic Region
4.1 World Historic Sulfonylureas for Type 2 Diabetes Market Size by Geographic Region (2021-2026)
4.1.1 Global Sulfonylureas for Type 2 Diabetes Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Sulfonylureas for Type 2 Diabetes Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Sulfonylureas for Type 2 Diabetes Market Size by Country/Region (2021-2026)
4.2.1 Global Sulfonylureas for Type 2 Diabetes Annual Sales by Country/Region (2021-2026)
4.2.2 Global Sulfonylureas for Type 2 Diabetes Annual Revenue by Country/Region (2021-2026)
4.3 Americas Sulfonylureas for Type 2 Diabetes Sales Growth
4.4 APAC Sulfonylureas for Type 2 Diabetes Sales Growth
4.5 Europe Sulfonylureas for Type 2 Diabetes Sales Growth
4.6 Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales Growth

5 Americas
5.1 Americas Sulfonylureas for Type 2 Diabetes Sales by Country
5.1.1 Americas Sulfonylureas for Type 2 Diabetes Sales by Country (2021-2026)
5.1.2 Americas Sulfonylureas for Type 2 Diabetes Revenue by Country (2021-2026)
5.2 Americas Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026)
5.3 Americas Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Sulfonylureas for Type 2 Diabetes Sales by Region
6.1.1 APAC Sulfonylureas for Type 2 Diabetes Sales by Region (2021-2026)
6.1.2 APAC Sulfonylureas for Type 2 Diabetes Revenue by Region (2021-2026)
6.2 APAC Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026)
6.3 APAC Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 Europe
7.1 Europe Sulfonylureas for Type 2 Diabetes by Country
7.1.1 Europe Sulfonylureas for Type 2 Diabetes Sales by Country (2021-2026)
7.1.2 Europe Sulfonylureas for Type 2 Diabetes Revenue by Country (2021-2026)
7.2 Europe Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026)
7.3 Europe Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Sulfonylureas for Type 2 Diabetes by Country
8.1.1 Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales by Country (2021-2026)
8.1.2 Middle East & Africa Sulfonylureas for Type 2 Diabetes Revenue by Country (2021-2026)
8.2 Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026)
8.3 Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Sulfonylureas for Type 2 Diabetes
10.3 Manufacturing Process Analysis of Sulfonylureas for Type 2 Diabetes
10.4 Industry Chain Structure of Sulfonylureas for Type 2 Diabetes

11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Sulfonylureas for Type 2 Diabetes Distributors
11.3 Sulfonylureas for Type 2 Diabetes Customer

12 World Forecast Review for Sulfonylureas for Type 2 Diabetes by Geographic Region
12.1 Global Sulfonylureas for Type 2 Diabetes Market Size Forecast by Region
12.1.1 Global Sulfonylureas for Type 2 Diabetes Forecast by Region (2027-2032)
12.1.2 Global Sulfonylureas for Type 2 Diabetes Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Sulfonylureas for Type 2 Diabetes Forecast by Type (2027-2032)
12.7 Global Sulfonylureas for Type 2 Diabetes Forecast by Application (2027-2032)

13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.1.3 Sanofi Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.2.3 Pfizer Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Teva
13.3.1 Teva Company Information
13.3.2 Teva Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.3.3 Teva Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Teva Main Business Overview
13.3.5 Teva Latest Developments
13.4 AdvaCare Pharma
13.4.1 AdvaCare Pharma Company Information
13.4.2 AdvaCare Pharma Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.4.3 AdvaCare Pharma Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 AdvaCare Pharma Main Business Overview
13.4.5 AdvaCare Pharma Latest Developments
13.5 Krka
13.5.1 Krka Company Information
13.5.2 Krka Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.5.3 Krka Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Krka Main Business Overview
13.5.5 Krka Latest Developments
13.6 Lupin Healthcare
13.6.1 Lupin Healthcare Company Information
13.6.2 Lupin Healthcare Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.6.3 Lupin Healthcare Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Lupin Healthcare Main Business Overview
13.6.5 Lupin Healthcare Latest Developments
13.7 Viatris (Mylan)
13.7.1 Viatris (Mylan) Company Information
13.7.2 Viatris (Mylan) Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.7.3 Viatris (Mylan) Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Viatris (Mylan) Main Business Overview
13.7.5 Viatris (Mylan) Latest Developments
13.8 Apotex Corporation
13.8.1 Apotex Corporation Company Information
13.8.2 Apotex Corporation Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.8.3 Apotex Corporation Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Apotex Corporation Main Business Overview
13.8.5 Apotex Corporation Latest Developments
13.9 Hoechst Canada
13.9.1 Hoechst Canada Company Information
13.9.2 Hoechst Canada Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.9.3 Hoechst Canada Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Hoechst Canada Main Business Overview
13.9.5 Hoechst Canada Latest Developments
13.10 Hikma Pharmaceuticals
13.10.1 Hikma Pharmaceuticals Company Information
13.10.2 Hikma Pharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.10.3 Hikma Pharmaceuticals Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Hikma Pharmaceuticals Main Business Overview
13.10.5 Hikma Pharmaceuticals Latest Developments
13.11 Servier Laboratories
13.11.1 Servier Laboratories Company Information
13.11.2 Servier Laboratories Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.11.3 Servier Laboratories Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Servier Laboratories Main Business Overview
13.11.5 Servier Laboratories Latest Developments
13.12 Aurobindo Pharma
13.12.1 Aurobindo Pharma Company Information
13.12.2 Aurobindo Pharma Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.12.3 Aurobindo Pharma Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Aurobindo Pharma Main Business Overview
13.12.5 Aurobindo Pharma Latest Developments
13.13 Zydus Cadila Healthcare
13.13.1 Zydus Cadila Healthcare Company Information
13.13.2 Zydus Cadila Healthcare Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.13.3 Zydus Cadila Healthcare Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Zydus Cadila Healthcare Main Business Overview
13.13.5 Zydus Cadila Healthcare Latest Developments
13.14 Accord Healthcare
13.14.1 Accord Healthcare Company Information
13.14.2 Accord Healthcare Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.14.3 Accord Healthcare Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Accord Healthcare Main Business Overview
13.14.5 Accord Healthcare Latest Developments
13.15 Taj Pharma
13.15.1 Taj Pharma Company Information
13.15.2 Taj Pharma Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.15.3 Taj Pharma Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Taj Pharma Main Business Overview
13.15.5 Taj Pharma Latest Developments
13.16 Boehringer Ingelheim
13.16.1 Boehringer Ingelheim Company Information
13.16.2 Boehringer Ingelheim Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.16.3 Boehringer Ingelheim Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Boehringer Ingelheim Main Business Overview
13.16.5 Boehringer Ingelheim Latest Developments
13.17 Qingdao Double Whale Pharmaceutical
13.17.1 Qingdao Double Whale Pharmaceutical Company Information
13.17.2 Qingdao Double Whale Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.17.3 Qingdao Double Whale Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Qingdao Double Whale Pharmaceutical Main Business Overview
13.17.5 Qingdao Double Whale Pharmaceutical Latest Developments
13.18 CHANGZHOU SUNLIGHT PHARMACEUTICAL
13.18.1 CHANGZHOU SUNLIGHT PHARMACEUTICAL Company Information
13.18.2 CHANGZHOU SUNLIGHT PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.18.3 CHANGZHOU SUNLIGHT PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 CHANGZHOU SUNLIGHT PHARMACEUTICAL Main Business Overview
13.18.5 CHANGZHOU SUNLIGHT PHARMACEUTICAL Latest Developments
13.19 Zhejiang Shapuaisi Pharmaceutical
13.19.1 Zhejiang Shapuaisi Pharmaceutical Company Information
13.19.2 Zhejiang Shapuaisi Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.19.3 Zhejiang Shapuaisi Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Zhejiang Shapuaisi Pharmaceutical Main Business Overview
13.19.5 Zhejiang Shapuaisi Pharmaceutical Latest Developments
13.20 DISHA PHARMACEUTICAL GROUP
13.20.1 DISHA PHARMACEUTICAL GROUP Company Information
13.20.2 DISHA PHARMACEUTICAL GROUP Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.20.3 DISHA PHARMACEUTICAL GROUP Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 DISHA PHARMACEUTICAL GROUP Main Business Overview
13.20.5 DISHA PHARMACEUTICAL GROUP Latest Developments
13.21 Shandong Lukang Pharmaceutical
13.21.1 Shandong Lukang Pharmaceutical Company Information
13.21.2 Shandong Lukang Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.21.3 Shandong Lukang Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Shandong Lukang Pharmaceutical Main Business Overview
13.21.5 Shandong Lukang Pharmaceutical Latest Developments
13.22 Beijing Jingfeng pharmaceutical
13.22.1 Beijing Jingfeng pharmaceutical Company Information
13.22.2 Beijing Jingfeng pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.22.3 Beijing Jingfeng pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Beijing Jingfeng pharmaceutical Main Business Overview
13.22.5 Beijing Jingfeng pharmaceutical Latest Developments
13.23 Suzhou Zhonghua Pharmaceutical Industry
13.23.1 Suzhou Zhonghua Pharmaceutical Industry Company Information
13.23.2 Suzhou Zhonghua Pharmaceutical Industry Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.23.3 Suzhou Zhonghua Pharmaceutical Industry Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Suzhou Zhonghua Pharmaceutical Industry Main Business Overview
13.23.5 Suzhou Zhonghua Pharmaceutical Industry Latest Developments
13.24 Shanghai SINE United Pharmaceuticals
13.24.1 Shanghai SINE United Pharmaceuticals Company Information
13.24.2 Shanghai SINE United Pharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.24.3 Shanghai SINE United Pharmaceuticals Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Shanghai SINE United Pharmaceuticals Main Business Overview
13.24.5 Shanghai SINE United Pharmaceuticals Latest Developments
13.25 Zhuhai United Pharmaceutical
13.25.1 Zhuhai United Pharmaceutical Company Information
13.25.2 Zhuhai United Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.25.3 Zhuhai United Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Zhuhai United Pharmaceutical Main Business Overview
13.25.5 Zhuhai United Pharmaceutical Latest Developments
13.26 Changzhou Siyao Pharmaceuticals
13.26.1 Changzhou Siyao Pharmaceuticals Company Information
13.26.2 Changzhou Siyao Pharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.26.3 Changzhou Siyao Pharmaceuticals Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Changzhou Siyao Pharmaceuticals Main Business Overview
13.26.5 Changzhou Siyao Pharmaceuticals Latest Developments
13.27 Shijiazhuang Yiling Pharmaceutical
13.27.1 Shijiazhuang Yiling Pharmaceutical Company Information
13.27.2 Shijiazhuang Yiling Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.27.3 Shijiazhuang Yiling Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.27.4 Shijiazhuang Yiling Pharmaceutical Main Business Overview
13.27.5 Shijiazhuang Yiling Pharmaceutical Latest Developments
13.28 Jiangsu Vanguard Pharmaceutical
13.28.1 Jiangsu Vanguard Pharmaceutical Company Information
13.28.2 Jiangsu Vanguard Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.28.3 Jiangsu Vanguard Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.28.4 Jiangsu Vanguard Pharmaceutical Main Business Overview
13.28.5 Jiangsu Vanguard Pharmaceutical Latest Developments
13.29 China Resources Shuanghe Pharmaceutical
13.29.1 China Resources Shuanghe Pharmaceutical Company Information
13.29.2 China Resources Shuanghe Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.29.3 China Resources Shuanghe Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.29.4 China Resources Shuanghe Pharmaceutical Main Business Overview
13.29.5 China Resources Shuanghe Pharmaceutical Latest Developments
13.30 TIPR PHARMACEUTICAL
13.30.1 TIPR PHARMACEUTICAL Company Information
13.30.2 TIPR PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.30.3 TIPR PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.30.4 TIPR PHARMACEUTICAL Main Business Overview
13.30.5 TIPR PHARMACEUTICAL Latest Developments
13.31 Jilin Jinheng Pharmaceutical
13.31.1 Jilin Jinheng Pharmaceutical Company Information
13.31.2 Jilin Jinheng Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.31.3 Jilin Jinheng Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.31.4 Jilin Jinheng Pharmaceutical Main Business Overview
13.31.5 Jilin Jinheng Pharmaceutical Latest Developments
13.32 Wanbang Biopharmaceuticals
13.32.1 Wanbang Biopharmaceuticals Company Information
13.32.2 Wanbang Biopharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.32.3 Wanbang Biopharmaceuticals Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.32.4 Wanbang Biopharmaceuticals Main Business Overview
13.32.5 Wanbang Biopharmaceuticals Latest Developments
13.33 Cspc Holdings Company
13.33.1 Cspc Holdings Company Company Information
13.33.2 Cspc Holdings Company Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
13.33.3 Cspc Holdings Company Sulfonylureas for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
13.33.4 Cspc Holdings Company Main Business Overview
13.33.5 Cspc Holdings Company Latest Developments

14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Sulfonylureas for Type 2 Diabetes Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Sulfonylureas for Type 2 Diabetes Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Glibenclamide
Table 4. Major Players of Glipizide
Table 5. Major Players of Gliclazide
Table 6. Major Players of Glizidone
Table 7. Major Players of Glimepiride
Table 8. Global Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026) & (K Units)
Table 9. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Type (2021-2026)
Table 10. Global Sulfonylureas for Type 2 Diabetes Revenue by Type (2021-2026) & ($ million)
Table 11. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Type (2021-2026)
Table 12. Global Sulfonylureas for Type 2 Diabetes Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Major Players of Original Drug
Table 14. Major Players of Generic Drug
Table 15. Global Sulfonylureas for Type 2 Diabetes Sales by Patent (2021-2026) & (K Units)
Table 16. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Patent (2021-2026)
Table 17. Global Sulfonylureas for Type 2 Diabetes Revenue by Patent (2021-2026) & ($ million)
Table 18. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Patent (2021-2026)
Table 19. Global Sulfonylureas for Type 2 Diabetes Sale Price by Patent (2021-2026) & (US$/Unit)
Table 20. Global Sulfonylureas for Type 2 Diabetes Sale by Application (2021-2026) & (K Units)
Table 21. Global Sulfonylureas for Type 2 Diabetes Sale Market Share by Application (2021-2026)
Table 22. Global Sulfonylureas for Type 2 Diabetes Revenue by Application (2021-2026) & ($ million)
Table 23. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Application (2021-2026)
Table 24. Global Sulfonylureas for Type 2 Diabetes Sale Price by Application (2021-2026) & (US$/Unit)
Table 25. Global Sulfonylureas for Type 2 Diabetes Sales by Company (2021-2026) & (K Units)
Table 26. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Company (2021-2026)
Table 27. Global Sulfonylureas for Type 2 Diabetes Revenue by Company (2021-2026) & ($ millions)
Table 28. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Company (2021-2026)
Table 29. Global Sulfonylureas for Type 2 Diabetes Sale Price by Company (2021-2026) & (US$/Unit)
Table 30. Key Manufacturers Sulfonylureas for Type 2 Diabetes Producing Area Distribution and Sales Area
Table 31. Players Sulfonylureas for Type 2 Diabetes Products Offered
Table 32. Sulfonylureas for Type 2 Diabetes Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 33. New Products and Potential Entrants
Table 34. Market M&A Activity & Strategy
Table 35. Global Sulfonylureas for Type 2 Diabetes Sales by Geographic Region (2021-2026) & (K Units)
Table 36. Global Sulfonylureas for Type 2 Diabetes Sales Market Share Geographic Region (2021-2026)
Table 37. Global Sulfonylureas for Type 2 Diabetes Revenue by Geographic Region (2021-2026) & ($ millions)
Table 38. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Geographic Region (2021-2026)
Table 39. Global Sulfonylureas for Type 2 Diabetes Sales by Country/Region (2021-2026) & (K Units)
Table 40. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Country/Region (2021-2026)
Table 41. Global Sulfonylureas for Type 2 Diabetes Revenue by Country/Region (2021-2026) & ($ millions)
Table 42. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Country/Region (2021-2026)
Table 43. Americas Sulfonylureas for Type 2 Diabetes Sales by Country (2021-2026) & (K Units)
Table 44. Americas Sulfonylureas for Type 2 Diabetes Sales Market Share by Country (2021-2026)
Table 45. Americas Sulfonylureas for Type 2 Diabetes Revenue by Country (2021-2026) & ($ millions)
Table 46. Americas Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026) & (K Units)
Table 47. Americas Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026) & (K Units)
Table 48. APAC Sulfonylureas for Type 2 Diabetes Sales by Region (2021-2026) & (K Units)
Table 49. APAC Sulfonylureas for Type 2 Diabetes Sales Market Share by Region (2021-2026)
Table 50. APAC Sulfonylureas for Type 2 Diabetes Revenue by Region (2021-2026) & ($ millions)
Table 51. APAC Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026) & (K Units)
Table 52. APAC Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026) & (K Units)
Table 53. Europe Sulfonylureas for Type 2 Diabetes Sales by Country (2021-2026) & (K Units)
Table 54. Europe Sulfonylureas for Type 2 Diabetes Revenue by Country (2021-2026) & ($ millions)
Table 55. Europe Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026) & (K Units)
Table 56. Europe Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026) & (K Units)
Table 57. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales by Country (2021-2026) & (K Units)
Table 58. Middle East & Africa Sulfonylureas for Type 2 Diabetes Revenue Market Share by Country (2021-2026)
Table 59. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales by Type (2021-2026) & (K Units)
Table 60. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales by Application (2021-2026) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Sulfonylureas for Type 2 Diabetes
Table 62. Key Market Challenges & Risks of Sulfonylureas for Type 2 Diabetes
Table 63. Key Industry Trends of Sulfonylureas for Type 2 Diabetes
Table 64. Sulfonylureas for Type 2 Diabetes Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Sulfonylureas for Type 2 Diabetes Distributors List
Table 67. Sulfonylureas for Type 2 Diabetes Customer List
Table 68. Global Sulfonylureas for Type 2 Diabetes Sales Forecast by Region (2027-2032) & (K Units)
Table 69. Global Sulfonylureas for Type 2 Diabetes Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Americas Sulfonylureas for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Americas Sulfonylureas for Type 2 Diabetes Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. APAC Sulfonylureas for Type 2 Diabetes Sales Forecast by Region (2027-2032) & (K Units)
Table 73. APAC Sulfonylureas for Type 2 Diabetes Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Europe Sulfonylureas for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (K Units)
Table 75. Europe Sulfonylureas for Type 2 Diabetes Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales Forecast by Country (2027-2032) & (K Units)
Table 77. Middle East & Africa Sulfonylureas for Type 2 Diabetes Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. Global Sulfonylureas for Type 2 Diabetes Sales Forecast by Type (2027-2032) & (K Units)
Table 79. Global Sulfonylureas for Type 2 Diabetes Revenue Forecast by Type (2027-2032) & ($ millions)
Table 80. Global Sulfonylureas for Type 2 Diabetes Sales Forecast by Application (2027-2032) & (K Units)
Table 81. Global Sulfonylureas for Type 2 Diabetes Revenue Forecast by Application (2027-2032) & ($ millions)
Table 82. Sanofi Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 83. Sanofi Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 84. Sanofi Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Sanofi Main Business
Table 86. Sanofi Latest Developments
Table 87. Pfizer Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 89. Pfizer Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Pfizer Main Business
Table 91. Pfizer Latest Developments
Table 92. Teva Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 93. Teva Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 94. Teva Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Teva Main Business
Table 96. Teva Latest Developments
Table 97. AdvaCare Pharma Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 98. AdvaCare Pharma Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 99. AdvaCare Pharma Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. AdvaCare Pharma Main Business
Table 101. AdvaCare Pharma Latest Developments
Table 102. Krka Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 103. Krka Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 104. Krka Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Krka Main Business
Table 106. Krka Latest Developments
Table 107. Lupin Healthcare Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 108. Lupin Healthcare Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 109. Lupin Healthcare Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Lupin Healthcare Main Business
Table 111. Lupin Healthcare Latest Developments
Table 112. Viatris (Mylan) Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 113. Viatris (Mylan) Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 114. Viatris (Mylan) Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Viatris (Mylan) Main Business
Table 116. Viatris (Mylan) Latest Developments
Table 117. Apotex Corporation Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 118. Apotex Corporation Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 119. Apotex Corporation Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Apotex Corporation Main Business
Table 121. Apotex Corporation Latest Developments
Table 122. Hoechst Canada Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 123. Hoechst Canada Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 124. Hoechst Canada Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Hoechst Canada Main Business
Table 126. Hoechst Canada Latest Developments
Table 127. Hikma Pharmaceuticals Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 128. Hikma Pharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 129. Hikma Pharmaceuticals Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Hikma Pharmaceuticals Main Business
Table 131. Hikma Pharmaceuticals Latest Developments
Table 132. Servier Laboratories Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 133. Servier Laboratories Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 134. Servier Laboratories Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Servier Laboratories Main Business
Table 136. Servier Laboratories Latest Developments
Table 137. Aurobindo Pharma Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 138. Aurobindo Pharma Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 139. Aurobindo Pharma Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Aurobindo Pharma Main Business
Table 141. Aurobindo Pharma Latest Developments
Table 142. Zydus Cadila Healthcare Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 143. Zydus Cadila Healthcare Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 144. Zydus Cadila Healthcare Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Zydus Cadila Healthcare Main Business
Table 146. Zydus Cadila Healthcare Latest Developments
Table 147. Accord Healthcare Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 148. Accord Healthcare Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 149. Accord Healthcare Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. Accord Healthcare Main Business
Table 151. Accord Healthcare Latest Developments
Table 152. Taj Pharma Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 153. Taj Pharma Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 154. Taj Pharma Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Taj Pharma Main Business
Table 156. Taj Pharma Latest Developments
Table 157. Boehringer Ingelheim Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 158. Boehringer Ingelheim Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 159. Boehringer Ingelheim Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Boehringer Ingelheim Main Business
Table 161. Boehringer Ingelheim Latest Developments
Table 162. Qingdao Double Whale Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 163. Qingdao Double Whale Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 164. Qingdao Double Whale Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Qingdao Double Whale Pharmaceutical Main Business
Table 166. Qingdao Double Whale Pharmaceutical Latest Developments
Table 167. CHANGZHOU SUNLIGHT PHARMACEUTICAL Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 168. CHANGZHOU SUNLIGHT PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 169. CHANGZHOU SUNLIGHT PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. CHANGZHOU SUNLIGHT PHARMACEUTICAL Main Business
Table 171. CHANGZHOU SUNLIGHT PHARMACEUTICAL Latest Developments
Table 172. Zhejiang Shapuaisi Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 173. Zhejiang Shapuaisi Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 174. Zhejiang Shapuaisi Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 175. Zhejiang Shapuaisi Pharmaceutical Main Business
Table 176. Zhejiang Shapuaisi Pharmaceutical Latest Developments
Table 177. DISHA PHARMACEUTICAL GROUP Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 178. DISHA PHARMACEUTICAL GROUP Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 179. DISHA PHARMACEUTICAL GROUP Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 180. DISHA PHARMACEUTICAL GROUP Main Business
Table 181. DISHA PHARMACEUTICAL GROUP Latest Developments
Table 182. Shandong Lukang Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 183. Shandong Lukang Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 184. Shandong Lukang Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 185. Shandong Lukang Pharmaceutical Main Business
Table 186. Shandong Lukang Pharmaceutical Latest Developments
Table 187. Beijing Jingfeng pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 188. Beijing Jingfeng pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 189. Beijing Jingfeng pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 190. Beijing Jingfeng pharmaceutical Main Business
Table 191. Beijing Jingfeng pharmaceutical Latest Developments
Table 192. Suzhou Zhonghua Pharmaceutical Industry Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 193. Suzhou Zhonghua Pharmaceutical Industry Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 194. Suzhou Zhonghua Pharmaceutical Industry Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 195. Suzhou Zhonghua Pharmaceutical Industry Main Business
Table 196. Suzhou Zhonghua Pharmaceutical Industry Latest Developments
Table 197. Shanghai SINE United Pharmaceuticals Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 198. Shanghai SINE United Pharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 199. Shanghai SINE United Pharmaceuticals Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 200. Shanghai SINE United Pharmaceuticals Main Business
Table 201. Shanghai SINE United Pharmaceuticals Latest Developments
Table 202. Zhuhai United Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 203. Zhuhai United Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 204. Zhuhai United Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 205. Zhuhai United Pharmaceutical Main Business
Table 206. Zhuhai United Pharmaceutical Latest Developments
Table 207. Changzhou Siyao Pharmaceuticals Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 208. Changzhou Siyao Pharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 209. Changzhou Siyao Pharmaceuticals Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 210. Changzhou Siyao Pharmaceuticals Main Business
Table 211. Changzhou Siyao Pharmaceuticals Latest Developments
Table 212. Shijiazhuang Yiling Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 213. Shijiazhuang Yiling Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 214. Shijiazhuang Yiling Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 215. Shijiazhuang Yiling Pharmaceutical Main Business
Table 216. Shijiazhuang Yiling Pharmaceutical Latest Developments
Table 217. Jiangsu Vanguard Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 218. Jiangsu Vanguard Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 219. Jiangsu Vanguard Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 220. Jiangsu Vanguard Pharmaceutical Main Business
Table 221. Jiangsu Vanguard Pharmaceutical Latest Developments
Table 222. China Resources Shuanghe Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 223. China Resources Shuanghe Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 224. China Resources Shuanghe Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 225. China Resources Shuanghe Pharmaceutical Main Business
Table 226. China Resources Shuanghe Pharmaceutical Latest Developments
Table 227. TIPR PHARMACEUTICAL Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 228. TIPR PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 229. TIPR PHARMACEUTICAL Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 230. TIPR PHARMACEUTICAL Main Business
Table 231. TIPR PHARMACEUTICAL Latest Developments
Table 232. Jilin Jinheng Pharmaceutical Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 233. Jilin Jinheng Pharmaceutical Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 234. Jilin Jinheng Pharmaceutical Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 235. Jilin Jinheng Pharmaceutical Main Business
Table 236. Jilin Jinheng Pharmaceutical Latest Developments
Table 237. Wanbang Biopharmaceuticals Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 238. Wanbang Biopharmaceuticals Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 239. Wanbang Biopharmaceuticals Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 240. Wanbang Biopharmaceuticals Main Business
Table 241. Wanbang Biopharmaceuticals Latest Developments
Table 242. Cspc Holdings Company Basic Information, Sulfonylureas for Type 2 Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 243. Cspc Holdings Company Sulfonylureas for Type 2 Diabetes Product Portfolios and Specifications
Table 244. Cspc Holdings Company Sulfonylureas for Type 2 Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 245. Cspc Holdings Company Main Business
Table 246. Cspc Holdings Company Latest Developments

List of Figures
Figure 1. Picture of Sulfonylureas for Type 2 Diabetes
Figure 2. Sulfonylureas for Type 2 Diabetes Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Sulfonylureas for Type 2 Diabetes Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Sulfonylureas for Type 2 Diabetes Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Sulfonylureas for Type 2 Diabetes Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Sulfonylureas for Type 2 Diabetes Sales Market Share by Country/Region (2025)
Figure 10. Sulfonylureas for Type 2 Diabetes Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Glibenclamide
Figure 12. Product Picture of Glipizide
Figure 13. Product Picture of Gliclazide
Figure 14. Product Picture of Glizidone
Figure 15. Product Picture of Glimepiride
Figure 16. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Type in 2026
Figure 17. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Original Drug
Figure 19. Product Picture of Generic Drug
Figure 20. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Patent in 2026
Figure 21. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Patent (2021-2026)
Figure 22. Sulfonylureas for Type 2 Diabetes Consumed in Hospital
Figure 23. Global Sulfonylureas for Type 2 Diabetes Market: Hospital (2021-2026) & (K Units)
Figure 24. Sulfonylureas for Type 2 Diabetes Consumed in Pharmacy
Figure 25. Global Sulfonylureas for Type 2 Diabetes Market: Pharmacy (2021-2026) & (K Units)
Figure 26. Global Sulfonylureas for Type 2 Diabetes Sale Market Share by Application (2025)
Figure 27. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Application in 2026
Figure 28. Sulfonylureas for Type 2 Diabetes Sales by Company in 2026 (K Units)
Figure 29. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Company in 2026
Figure 30. Sulfonylureas for Type 2 Diabetes Revenue by Company in 2026 ($ millions)
Figure 31. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Company in 2026
Figure 32. Global Sulfonylureas for Type 2 Diabetes Sales Market Share by Geographic Region (2021-2026)
Figure 33. Global Sulfonylureas for Type 2 Diabetes Revenue Market Share by Geographic Region in 2026
Figure 34. Americas Sulfonylureas for Type 2 Diabetes Sales 2021-2026 (K Units)
Figure 35. Americas Sulfonylureas for Type 2 Diabetes Revenue 2021-2026 ($ millions)
Figure 36. APAC Sulfonylureas for Type 2 Diabetes Sales 2021-2026 (K Units)
Figure 37. APAC Sulfonylureas for Type 2 Diabetes Revenue 2021-2026 ($ millions)
Figure 38. Europe Sulfonylureas for Type 2 Diabetes Sales 2021-2026 (K Units)
Figure 39. Europe Sulfonylureas for Type 2 Diabetes Revenue 2021-2026 ($ millions)
Figure 40. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales 2021-2026 (K Units)
Figure 41. Middle East & Africa Sulfonylureas for Type 2 Diabetes Revenue 2021-2026 ($ millions)
Figure 42. Americas Sulfonylureas for Type 2 Diabetes Sales Market Share by Country in 2026
Figure 43. Americas Sulfonylureas for Type 2 Diabetes Revenue Market Share by Country (2021-2026)
Figure 44. Americas Sulfonylureas for Type 2 Diabetes Sales Market Share by Type (2021-2026)
Figure 45. Americas Sulfonylureas for Type 2 Diabetes Sales Market Share by Application (2021-2026)
Figure 46. United States Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 47. Canada Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 48. Mexico Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 49. Brazil Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 50. APAC Sulfonylureas for Type 2 Diabetes Sales Market Share by Region in 2026
Figure 51. APAC Sulfonylureas for Type 2 Diabetes Revenue Market Share by Region (2021-2026)
Figure 52. APAC Sulfonylureas for Type 2 Diabetes Sales Market Share by Type (2021-2026)
Figure 53. APAC Sulfonylureas for Type 2 Diabetes Sales Market Share by Application (2021-2026)
Figure 54. China Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 55. Japan Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 56. South Korea Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 57. Southeast Asia Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 58. India Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 59. Australia Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 60. China Taiwan Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 61. Europe Sulfonylureas for Type 2 Diabetes Sales Market Share by Country in 2026
Figure 62. Europe Sulfonylureas for Type 2 Diabetes Revenue Market Share by Country (2021-2026)
Figure 63. Europe Sulfonylureas for Type 2 Diabetes Sales Market Share by Type (2021-2026)
Figure 64. Europe Sulfonylureas for Type 2 Diabetes Sales Market Share by Application (2021-2026)
Figure 65. Germany Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 66. France Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 67. UK Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 68. Italy Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 69. Russia Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 70. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales Market Share by Country (2021-2026)
Figure 71. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales Market Share by Type (2021-2026)
Figure 72. Middle East & Africa Sulfonylureas for Type 2 Diabetes Sales Market Share by Application (2021-2026)
Figure 73. Egypt Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)
Figure 74. South Africa Sulfonylureas for Type 2 Diabetes Revenue Growth 2021-2026 ($ millions)